Drugs / Emtricitabine Tenofovir Alafenamide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04616963 | Oct 2019 → Jan 2024 overdue | HIV infectious disease | University of California, San Diego | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emtricitabine Tenofovir Alafenamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04616963 ↗ |
| Route | Oral | “fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II” NCT04616963 ↗ |